In 2023, Alphamab Oncology completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).
However, Alphamab Oncology has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2023 | 2022 | 2021 | 2020-2019 |
|---|---|---|---|---|
Total Scope 1 | 3,969.51a | 3,605.45a | 2,868.37a | |
Total Scope 2 | ||||
Unspecified Calculation Method | 8,791.3a | 7,857.37a | 7,052.02a | |
Total Scope 3 | N/A | N/A | N/A | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 128.9518a | 150.4696a | 125.1706a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2023, the total operational greenhouse gas (GHG) emissions of Alphamab Oncology amounted to 12,760.81 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2022, the total operational greenhouse gas (GHG) emissions of Alphamab Oncology increased by 11.32%, suggesting that the company faced challenges in reducing its emissions from its core operations.a
In 2023, the total Scope 1 emissions of Alphamab Oncology were 3,969.51 metric tons of CO₂ equivalent (tCO₂e).a
Since 2020, Alphamab Oncology's Scope 1 emissions have increased by 76.47%, reflecting a rising long-term trend in Scope 1 emissions over time.ab
Compared to the previous year (2022), Alphamab Oncology's Scope 1 emissions increased by 10.1%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.a
In 2023, Alphamab Oncology reported Scope 2 greenhouse gas (GHG) emissions of 8,791.3 tCO₂e without specifying the calculation method.a
Since 2020, Alphamab Oncology's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have increased by 45.26%, reflecting a rising long-term trend in Scope 2 emissions over time.ab
Compared to the previous year (2022), Alphamab Oncology's Scope 2 emissions (Unspecified Calculation Method) rose by 11.89% in 2023, suggesting that the company faced challenges in reducing emissions from purchased electricity and energya
In 2023, Alphamab Oncology reported its Scope 2 emissions using an unspecified methodology.a
In 2023, Alphamab Oncology reported Scope 1 greenhouse gas (GHG) emissions of 3,969.51 tCO₂e and total revenues of USD 31 millions. This translates into an emissions intensity of 128.95 tCO₂e per millions USD.a
In 2023, Alphamab Oncology reported a Scope 1 emissions intensity of 128.95 tCO₂e per millions USD. Compared to the peer group median of 10.66, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a
In 2023, Alphamab Oncology ranked 24 out of 23 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
This places Alphamab Oncology among the least efficient performers, with one of the highest emissions intensities in its sector.a